

RESEARCH

Open Access



Clinical-epidemiological characteristics and maternal-foetal outcomes in pregnant women hospitalised with COVID-19 in Venezuela: a retrospective study

Fhabían S. Carrión-Nessi^{1,2*†}, Mercedes P. Castro^{3†}, Diana C. Freitas-De Nobrega^{1,2}, Augusto Moncada-Ortega^{1,4}, Óscar D. Omaña-Ávila^{1,5}, Daniela L. Mendoza-Millán^{1,5}, María V. Marcano-Rojas¹, Nayren J. Trejo², Isabella V. Virriel², Melynar Chavero¹, Natasha A. Camejo-Ávila^{1,2}, Alfonso J. Rodríguez-Morales^{6,7,8} and David A. Forero-Peña^{1,9*}

Abstract

Background: In low- and middle-income countries, pregnant women and newborns are more vulnerable to adverse outcomes from coronavirus disease 2019 (COVID-19). However, in Venezuela, there are no integrated data in a national surveillance system to identify the clinical-epidemiological characteristics and maternal-foetal outcomes of pregnant women hospitalised with COVID-19.

Methods: A retrospective study was conducted among Venezuelan pregnant women hospitalised with COVID-19 seen at the “Ruiz y Páez” University Hospital Complex and the San Cristobal Central Hospital between June 2020 and September 2021. Information was obtained from physical and digitised clinical records using a purpose-designed proforma to collect epidemiological, clinical, paraclinical, treatment, obstetric and perinatal complications, and maternal-foetal outcomes data.

Results: A total of 80 pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection were seen within the study period, 59 (73.8%) survived and 21 (26.2%) died. The median (interquartile range) age was 29 (23–33) years, the majority being in the third trimester of pregnancy (81.2%; $n = 65$). Interestingly, four (5%) pregnant women were co-infected with malaria by *Plasmodium vivax* and three (3.8%) with syphilis. The most frequent symptoms were fever (75%; $n = 60$), dry cough (68.8%; $n = 55$), dyspnoea (55%; $n = 44$), and headache (53.8%; $n = 43$). The most frequent maternal complications were anaemia (51.5%; $n = 66$) and hypertensive disorders of pregnancy (17.5%; $n = 14$). The most frequent perinatal complications were preterm delivery (39.2%; $n = 20/51$) and oligohydramnios (31.3%; $n = 25$). A total of 29 (36.3%) adverse foetal outcomes were documented, 21 stillbirth and eight abortions.

[†]Fhabían S. Carrión-Nessi and Mercedes P. Castro are contributed equally to this work and share the first authorship.

*Correspondence: fhabiancarrion@gmail.com; vacter.cv@gmail.com

¹ Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela

⁹ Infectious Diseases Department, University Hospital of Caracas, Caracas, Venezuela

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusion: This is the first study to describe the clinical-epidemiological behaviour of COVID-19 in hospitalised Venezuelan pregnant women. Anaemia, hypertensive disorders of pregnancy, oligohydramnios, and low birth weight were the most frequent maternal-foetal complications in this population of pregnant women.

Keywords: COVID-19, Pregnancy, Epidemiology, Maternal-foetal outcome, Venezuela

Background

Latin America is one of the most affected regions by the coronavirus disease 2019 (COVID-19) pandemic, showing the highest morbidity and mortality rates in countries with weakened healthcare services, economic and political instabilities, humanitarian crises, and deep social inequalities, such as Venezuela [1–3]. As of 30 November 2022, 547,465 cases and 5,828 deaths from COVID-19 had been reported in Venezuela, some of the lowest reported numbers in the region. However, these data are inconsistent with the real epidemiological behaviour of the pandemic in the country, where underreporting is estimated to be five to seven times higher [4].

Anatomical, physiological, and immunological changes accompanying pregnancy may increase the susceptibility of pregnant women to viral pathogens and the risk of developing severe pneumonia [5]. In addition, studies of other coronavirus infections, such as severe acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus, suggest that infected pregnant women may be more susceptible to adverse outcomes, such as intubation, intensive care unit admission, renal failure, and death [6], as well as an increased risk of neonatal mortality, preterm delivery, and foetal growth restriction [7–9].

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasingly well understood, outcomes associated with infection during pregnancy remain limited and unclear. At the pandemic's beginning, scientific reports suggested that pregnant women were not at increased risk of maternal-foetal complications due to COVID-19 [10, 11]. Current knowledge on the impact of SARS-CoV-2 infection in pregnant women has been mainly derived from case reports, case series, and population-based surveillance systems in high-income countries. These data have focused primarily on maternal outcomes in women with symptomatic disease, with maternal death, intrauterine foetal death, and neonatal death reported in approximately 1% of cases in this setting [12–14]. In addition, several studies have described that exposure to COVID-19 increases the likelihood of developing pre-eclampsia/eclampsia, preterm delivery, premature rupture of membrane, and admission to the neonatal intensive care unit [15, 16].

In low- and middle-income countries (LMICs), pregnant women and newborns are more vulnerable to

adverse outcomes from COVID-19 [17, 18]. However, to date, there is limited information on the epidemiological and clinical characteristics of COVID-19 in pregnant women in Latin America [19]. In the case of Venezuela, no data is integrated into a national surveillance system to identify maternal-foetal characteristics or the outcomes of hospital admissions of pregnant women for COVID-19. Therefore, this study aimed to evaluate the clinical-epidemiological characteristics and maternal-foetal outcomes in pregnant women with COVID-19 hospitalised in two sentinel centres in Venezuela.

Methods

Patients and study design

A retrospective study was conducted including all pregnant women with SARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) who were hospitalised in two sentinel centres for the care of patients with COVID-19 in Venezuela, the “Ruiz y Páez” University Hospital Complex, Bolívar state and the San Cristobal Central Hospital, Tachira state, between June 2020 and September 2021. Pregnant women with missing epidemiological, clinical, treatment, obstetric and perinatal complications, and maternal-foetal outcomes data in their medical records, were excluded.

Data collection

Information was obtained from physical and digitised clinical records using a purpose-designed proforma to collect epidemiological (age, race, provenance by state), clinical (admission symptoms, gynaecobstetric characteristics, pathological history, psychobiological habits, physical examination), paraclinical (haematology, blood chemistry, coagulation tests), treatment (antivirals, antibiotics, antiparasitic, thromboprophylaxis, corticosteroids, oxygen therapy), obstetric (maternal anaemia, hypertensive disorders of pregnancy, pre- and postpartum haemorrhage, maternal sepsis) and perinatal (premature rupture of membranes, placenta praevia, premature detachment of the normally inserted placenta, foetal growth restriction, oligohydramnios) complications, and maternal-foetal outcomes data.

Statistical analysis

The following descriptive statistics summarised pregnant women's data: mean, standard deviation (SD), median, interquartile range (IQR), and frequency (%). Kolmogorov–Smirnov test assessed the distribution of variables. Median test was used for variables with a non-normal distribution, and Student's t-test for those with normal distribution. Pearson's chi-squared and Fisher's exact tests were used for categorical variables. When the need for *post-hoc* analysis was detected, the Bonferroni correction of the *p*-value was used to adjust it. *P*-values < 0.05 were considered significant. Due to the small sample size, binomial regression data modelling did not detect risk factors associated with maternal and foetal mortality. Statistical analysis was performed using Statistical Package for the Social Sciences version 26 (International Business Machines Corporation, Armonk, NY, United States). Figures were generated using Microsoft® Excel® version 2019 (Microsoft, Redmond, WA, United States).

Results

Epidemiological and gynaecobstetric characteristics and medical history of pregnant women with COVID-19

Eighty pregnant women with SARS-CoV-2 infection confirmed by RT-PCR were included. Of these, 59 (73.8%) survived and 21 (26.2%) died. The median (IQR) age of pregnant women was 29 (23–33) years; most were of mixed race (85%; *n* = 68) and in the third trimester of pregnancy (81.2%; *n* = 65). No statistically significant differences were found between the epidemiological and gynaecobstetric characteristics of the surviving and dead pregnant women (Table 1). The most frequent co-morbidity was obesity (27.5%; *n* = 22), followed by hypertension (3.8%; *n* = 3) and diabetes (3.8%; *n* = 3). Interestingly, four (5%) pregnant women were co-infected with malaria by *Plasmodium vivax* and three (3.8%) with syphilis. Obesity was more common in dead pregnant women (38.1%) compared to survivors (23.7%); however, no statistically significant differences were found (*p* = 0.205).

Table 1 Epidemiological and gynaecobstetric characteristics and medical history of 80 pregnant women with confirmed SARS-CoV-2 infection in Venezuela

	All (N = 80)	Survivors (N = 59)	Dead (N = 21)	<i>p</i> -value
<i>Epidemiological characteristics</i>				
Age, median (IQR), years	29 (23–33)	28 (23–33)	29 (23–33)	0.464*
Age group, <i>n</i> (%)				0.946†
≤ 20 years	15 (18.8)	11 (18.6)	4 (19)	
21–30 years	36 (45)	26 (44.1)	40 (47.7)	
≥ 31 years	29 (36.2)	22 (37.3)	7 (33.3)	
Race, <i>n</i> (%)				0.507†
Mixed	68 (85)	50 (84.7)	18 (85.7)	
White	6 (7.5)	4 (6.8)	2 (9.5)	
Black	4 (5)	4 (6.8)	0 (0)	
Indigenous	2 (2.5)	1 (1.7)	1 (4.8)	
Provenance by state, <i>n</i> (%)				0.138‡
Bolivar	47 (58.8)	31 (52.5)	16 (76.2)	
Tachira	30 (37.5)	25 (42.4)	5 (23.8)	
Anzoategui	3 (3.7)	3 (5.1)	0 (0)	
<i>Gynaecobstetric characteristics</i>				
Trimester of pregnancy, <i>n</i> (%)				0.305†
First trimester	3 (3.8)	2 (3.4)	1 (4.8)	
Second trimester	12 (15)	11 (18.6)	1 (4.8)	
Third trimester	65 (81.2)	46 (78)	19 (90.4)	
No. of previous pregnancies, <i>n</i> (%)				0.732†
0	20 (25)	16 (27.1)	4 (19)	
1–3	54 (67.5)	39 (66.1)	15 (71.4)	
4–6	6 (7.5)	4 (6.8)	2 (9.5)	

* Median test

† Pearson's chi-square test

‡ Fisher's exact test

IQR interquartile range

Clinical characteristics of pregnant women with COVID-19

The median (IQR) time from symptom onset to hospitalisation was 6 (2–8) days, with no statistically significant difference between surviving and dead pregnant women ($p=0.47$). The median (IQR) time from symptom onset to labour was 12 (7–18.5) days. The median (IQR) time from symptom onset to maternal death was 7 (6–16) days. Fever (75%; $n=60$), dry cough (68.8%; $n=55$), dyspnoea (55%; $n=44$), and headache (53.8%; $n=43$) were the most frequent symptoms in all pregnant women; the least frequent symptoms were dizziness (2.5%; $n=2$), chest pain (2.5%; $n=2$), and rhinorrhoea (2.5%; $n=2$). A higher proportion of dyspnoea, vomiting, and wet cough were found in dead pregnant women compared to survivors (76.2% vs. 47.5%, $p=0.023$; 19% vs. 3.4%, $p=0.038$; 23.8% vs. 1.7%, $p=0.004$; respectively) (Fig. 1).

On physical examination, median heart rate and median respiratory rate were significantly higher in dead pregnant women compared with survivors (101 [86–112] vs. 85 [80–98], $p=0.015$; 24 [20–29] vs. 19 [18–22], $p=0.007$; respectively), while median oxygen saturation was significantly higher in surviving pregnant women compared to dead (94 [90–97] vs. 81 [72–89], $p<0.001$). A higher proportion of oxygen saturation $\geq 94\%$ was found in surviving pregnant women compared to dead (54.2% vs. 14.3%, $p<0.001$), while a higher proportion of oxygen saturation $<80\%$ was found in dead pregnant women compared to survivors (47.6% vs. 6.8%, $p<0.001$). Altered consciousness was more frequent in dead pregnant women than in those who survived (5% [$n=4$] vs. 1.25% [$n=1$], $p=0.016$).

Paraclinical findings of pregnant women with COVID-19

Table 2 shows the paraclinical findings. No statistically significant differences were observed between the paraclinical results of surviving and dead pregnant women. Median lactate dehydrogenase was higher in dead pregnant women than in survivors (482 [297–1520] vs. 258 [163–557] mg/dL); however, there was no statistically significant difference ($p=0.263$).

Maternal and perinatal complications and foetal outcomes of pregnant women with COVID-19

The most frequent maternal and perinatal complications were anaemia (51.5%; $n=66$), oligohydramnios (31.3%; $n=25$), and hypertensive disorders of pregnancy (17.5%; $n=14$) (Table 3).

Almost all pregnant women received antibiotic therapy (96.3%; $n=77$), the most frequent being Ceftriaxone (63.6%; $n=49$), followed by Vancomycin (59.7%; $n=46$), and Cephalothin (16.8%; $n=13$). Pregnant women with *Plasmodium vivax* co-infection received different antiparasitic drugs for malaria treatment (Chloroquine: 3.8%, and Artesunate injection: 1.3%). A higher proportion of anticoagulant use (Enoxaparin) was found in dead pregnant women compared to survivors (81% vs. 55.9%, $p=0.042$). Regarding corticosteroids, 37.5% ($n=30$) of pregnant women received Dexamethasone or Methylprednisolone, with no statistically significant difference between surviving and dead pregnant women ($p=0.595$). Maternal non-invasive mechanical ventilation was necessary for eight pregnant women (10%), and one required invasive mechanical ventilation (1.3%).




Fig. 1 Symptoms of 80 pregnant women with confirmed SARS-CoV-2 infection in Venezuela. * $p < 0.05$ (p -values by Pearson's chi-square).

Table 2 Paraclinical findings in 80 pregnant women with confirmed SARS-CoV-2 infection in Venezuela

	All (N = 80)	Survivors (N = 59)	Dead (N = 21)	p-value
Haemoglobin, median (IQR), g/dL (n = 66)	10.9 (9.8–11.5)	11 (9.8–11.8)	10.7 (9.7–11)	0.619*
Haematocrit, median (IQR), % (n = 66)	33 (29.6–35.9)	33 (30–36)	32 (29.4–34)	0.694*
Leukocytes, median (IQR), $\times 10^3/\text{mL}$ (n = 66)	9.5 (7.7–12.9)	9.5 (7.7–12.9)	9.2 (8.3–12.6)	1*
Neutrophils, mean (SD), $\times 10^3/\text{mL}$ (n = 66)	78 (10)	78 (10)	82 (8)	0.61†
Lymphocytes, mean (SD), $\times 10^3/\text{mL}$ (n = 66)	21 (10)	20 (11)	17 (16)	0.63†
Platelets, median (IQR), $\times 10^3/\text{mL}$ (n = 66)	185 (155–222)	187 (165–220)	150 (138–245)	0.619*
Glycaemia, mean (SD), mg/dL (n = 46)	93 (19)	89 (18)	103 (18)	0.769†
Urea, median (IQR), mg/dL (n = 36)	20.5 (15.5–34)	20 (14–28.5)	22 (15–45)	0.289*
Creatinine, median (IQR), mg/dL (n = 36)	0.8 (0.7–1)	0.8 (0.7–0.9)	0.9 (0.7–1.4)	0.724*
PT, median (IQR), seconds (n = 14)	12.4 (12–15)	12.9 (11.3–15.8)	12.0 (11.3–12.8)	0.559*
PTT, median (IQR), seconds (n = 14)	31.4 (30–33.2)	32.4 (30–33.2)	29 (27.5–32.5)	0.263*
AST, mean (SD), mg/dL (n = 13)	51.5 (19.2)	50.4 (20.8)	57.5 (4.9)	0.152†
ALT, mean (SD), mg/dL (n = 13)	49.3 (23.8)	51.2 (25.4)	38.5 (7.8)	0.194†
LDH, median (IQR), mg/dL (n = 53)	301 (180–587)	258 (163–557)	482 (297–1520)	0.263*
D-dimer, median (IQR), ng/dL (n = 42)	19.0 (11.1–22.9)	19.2 (11.1–22.6)	18.9 (12.9–27.2)	0.717*
Ferritin, median (IQR), ng/dL (n = 42)	288 (180–450)	280 (180–410)	320 (200–689)	0.452*

* Median test

† Student's t-test

IQR interquartile range, PT prothrombin time, PTT partial thromboplastin time, LDH lactate dehydrogenase

Table 3 Maternal and perinatal complications in 80 pregnant women with confirmed SARS-CoV-2 infection in Venezuela

	All (N = 80)	Survivors (N = 59)	Dead (N = 21)	p-value
<i>Maternal complications, n (%)</i>				
Anaemia	66 (51.5)	53 (49.1)	13 (61.5)	0.420*
Hypertensive disorders of pregnancy	14 (17.5)	12 (20.3)	2 (9.5)	0.263*
<i>Perinatal complications, n (%)</i>				
Oligohydramnios	25 (31.3)	22 (37.3)	3 (14.3)	0.051*
Premature rupture of membranes	5 (6.3)	5 (8.5)	0 (0)	0.208†
Foetal growth restriction	3 (3.8)	3 (5.1)	0 (0)	0.396†
Placenta praevia	1 (1.3)	1 (1.7)	0 (0)	0.737†
Premature detachment of the normally inserted placenta	1 (1.3)	1 (1.7)	0 (0)	0.737†

* Pearson's chi-square test

† Fisher's exact test

There were 29 adverse foetal outcomes, 21 (26.2%) still-birth and eight (10%) abortions. A higher proportion of abortions was found in dead pregnant women compared to survivors (23.8% vs. 5.1%, $p=0.014$). Of the live newborns, most were delivered by caesarean section (92.2%; $n=47/51$), preterm (39.2%; $n=20/51$) and with low birth weight (53.6%; $n=27/51$); however, with suitable adaptation status (7–10 points) at the fifth (86.3%; $n=44/51$) minute by APGAR score. Term delivery was more frequent in survivors compared to the dead ($p=0.026$). Severely depressed live births at the fifth minute by APGAR score were more frequent in dead pregnant

women than in survivors (37.5% [$n=3$] vs. 0% [$n=0$], $p<0.001$) (Table 4). Only eight newborns survived out of the 21 pregnant women died.

Discussion

This study describes the primary maternal and foetal outcomes among pregnant women hospitalised with COVID-19 in two sentinel centres in Venezuela. The median age and trimester of pregnancy at the presentation of our pregnant women were similar to those reported in other studies [20, 21]. Obesity, hypertension, and diabetes were observed in similar frequencies

Table 4 Foetal outcomes in 80 pregnant women with confirmed SARS-CoV-2 infection in Venezuela

	All (N = 80)	Survivors (N = 59)	Dead (N = 21)	p-value
<i>Foetal outcome, n (%)</i>				
Stillbirth	21 (26.2)	13 (22)	8 (38.1)	0.151*
Abortion	8 (10)	3 (5.1)	5 (23.8)	0.014*
Live birth	51 (63.8)	43 (72.9)	8 (38.1)	
Type of delivery, n (%) (n = 51)				0.494†
Caesarean section	47 (92.2)	39 (90.7)	8 (100)	
Vaginal	4 (7.8)	4 (9.3)	0 (0)	
Gestational age at delivery, n (%) (n = 51)				0.026*
Term (37–41 ⁺ 6)	31 (60.8)	28 (65.1)	3 (37.5)	
Late preterm (34–36 ⁺ 6)	7 (13.7)	6 (14)	1 (12.5)	
Moderate preterm (32–33 ⁺ 6)	7 (13.7)	4 (9.3)	3 (37.5)	
Very preterm (28–31 ⁺ 6)	5 (9.8)	5 (11.6)	0 (0)	
Extreme preterm (< 28)	1 (2)	0 (0)	1 (12.5)	
Birth weight, n (%) (n = 51)				0.352*
Normal weight (2500–3750 g)	24 (47.1)	22 (51.2)	2 (25.0)	
Low birth weight (1500–2499 g)	21 (41.8)	16 (37.2)	5 (62.5)	
Very low birth weight (1000–1499 g)	6 (11.8)	5 (11.6)	1 (12.5)	
APGAR score at 5th minute, n (%) (n = 51)				
7–10	44 (86.3)	40 (93.0)	4 (50.0)	0.001*‡
4–6	4 (7.8)	3 (7.0)	1 (12.5)	0.596*‡
0–3	3 (5.8)	0 (0.0)	3 (37.5)	< 0.001*‡

* Pearson's chi-square test

† Fisher's exact test

‡ Statistically significant p-value according to Bonferroni correction = 0.008

to previously documented [21–23]. A group of pregnant women reported co-infection with malaria and syphilis, in accordance with co-infections reported in LMICs [17, 24]. Consistent with previous publications [20, 21, 25, 26], our study found that fever, headache, cough, and dyspnoea were the most frequent symptoms reported by pregnant women with COVID-19 at consultation and hospital admission.

Overall estimates in low-risk pregnancies for pre-eclampsia and eclampsia are 4.6 and 1.4%, respectively, with wide variation between regions. In this study, hypertensive pregnancy syndrome was the most frequent maternal complication (17.5%), similar to previous reports [21, 27]. Hypertensive disorders of pregnancy and COVID-19 share an exaggerated inflammatory response, guided by cytokines such as IL-6, TNF- α and IFN- γ leading to endothelial damage [28]. Likewise, studies in Latin America [21] and other regions of the world [14–16, 29] found that preterm delivery and low birth weight were the most frequent perinatal complications in our patient population, which could be associated with excessive host inflammatory response to COVID-19 and poor foetal vascular perfusion of the placenta [14]. In our study, oligohydramnios was documented in almost one-third

(31.3%) of pregnant women, which contrasts with other studies [21], where an incidence of 3% (10 times lower) was reported. That could be explained by the measurement variability of this parameter, which depends on the operator/echographer performing it in each institution. Nevertheless, this study demonstrated an increased risk of maternal and perinatal morbidity and mortality associated with SARS-CoV-2 infection, likely due to difficult access to health care and reduced healthcare workers and intensive care unit beds in LMICs, such as Venezuela.

Although the low frequency of bacterial superinfection in patients with COVID-19 (6.9–8%) is documented [30, 31], our study reported that almost all (96.3%) pregnant women received at least one course of antibiotic therapy during their hospitalisation. However, indiscriminate antibiotic use during the pandemic has been the common denominator (71–90%) [31], a clinical practice that increases bacterial multidrug resistance [30, 32, 33]. On the other hand, the prothrombotic risk in pregnant women with SARS-CoV-2 infection has been reported previously [34]. Therefore, particular recommendations have been made on using antithrombotic prophylaxis or anticoagulation in pregnant women [35]. We found here a higher proportion of anticoagulant use in dead

pregnant women than in survivors. However, it is impossible to conclude because it is necessary to consider unassessed variables such as dose, disease severity, and even the timing of the pandemic, as the role and indication of antithrombotics in managing COVID-19 were unknown at the beginning of the pandemic.

Among the maternal outcomes, we found an extremely high case fatality ratio (26.2%) compared with similar studies [16, 36], associated with the presence of poor prognosis markers such as elevated lactate dehydrogenase, C-reactive protein, ferritin, and D dimer, as well as thrombocytopenia and lymphopenia [30, 37–49]. An increased risk of abortions and stillbirth in patients with COVID-19 has been described in larger studies [17, 50, 51], a pattern observed in our study with a higher proportion within the dead pregnant women, similar to that described in a Latin-American study [21], with the exception of the proportion of stillbirth. A possible hypothesis that could explain these discrepancies is poor antenatal care due to the collapse of health care centres during the COVID-19 pandemic in Venezuela, as well as quarantine and community containment measures [52]. Additionally, the retrospective nature of our study, which only included hospitalised pregnant women, and the limited access to routine screening for SARS-CoV-2 infection among pregnant women, may have contributed to this percentage difference in mortality.

There is evidence that corticosteroids reduce mortality, hospitalisation time, and use of mechanical ventilation in COVID-19 patients with supplemental oxygen requirements [53], so they have been applied as an indispensable tool, even in pregnant women [54]. In this study, more than one-third of pregnant women (37.5%) received some form of corticosteroid; however, the number is lower than that of pregnant women with supplemental oxygen requirements (52.5%). There is substantial evidence to support the use of corticosteroids in pregnant women at risk of preterm delivery [30], one of the complications with the highest incidence in our study.

This study has multiple limitations. In the first place, the design of the retrospective study did not allow obtaining the direct cause of maternal death, maternal COVID-19 vaccination status, total number of maternal admissions in the study period or socio-economic data due to the deterioration of the statistical recording system and medical records in the two sentinel sites of our study. Similarly, not all the paraclinical studies of pregnant women were obtained, limiting their analysis. Second, it includes a small number of patients, which limits the multivariable analysis design for identifying risk factors associated with mortality. Third, despite including pregnant women from two sentinel centres for the care of patients with COVID-19, our results cannot be

extrapolated to the general population since the availability of intensive care beds varies between different hospitals as the complexity of caring for pregnant women. Finally, it is possible that the clinician's decision was decisive at the time of patient admission, leading him to admit pregnant women with COVID-19 with mild symptoms only for surveillance and foetal evaluation, so the additional admission criteria of each institution and even between each specialist limit the interpretation of our results. Therefore, prospective, longitudinal, and multicentre studies are needed to understand better the factors associated with maternal mortality from COVID-19 in Venezuela.

Conclusions

This study describes the clinical-epidemiological behaviour of COVID-19 in hospitalised Venezuelan pregnant women. Anaemia, hypertensive syndrome of pregnancy, oligohydramnios, and low birth weight were the most frequent maternal-foetal complications in our patient population. Therefore, it is recommended to establish a national surveillance system for pregnant women with COVID-19 and to carry out multicentre studies to identify risk factors associated with mortality in this patient population.

Abbreviations

COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; RT-PCR: Reverse transcriptase polymerase chain reaction; SD: Standard deviation; IQR: Interquartile range.

Acknowledgements

We thank patients from the Obstetrics and Gynaecology Department of the "Ruiz y Páez" University Hospital Complex and the San Cristobal Central Hospital and the research staff involved in the work.

Authors' contributions

FSC-N, MPC, and DAF-P conceived and designed the study. FSC-N, MPC, NJT, IVV, and MC collected clinical data. FSC-N, DCF-dN, AM-O, ÓDO-Á, DLM-M, MVM-R, NAC-Á, and DAF-P analysed and interpreted the data. FSC-N, DCF-dN, AM-O, ÓDO-Á, AJR-M, and DAF-P wrote the manuscript. FSC-N, MPC, AJR-M, and DAF-P critically reviewed the manuscript. All authors reviewed and approved the final version of the manuscript.

Funding

The authors received no specific funding for this work.

Availability of data and materials

All data generated or analysed during this study are included in this article.

Declarations

Ethics approval and consent to participate

The study protocol was reviewed and approved by the National Centre for Bioethics (CENABI, in Spanish) of Venezuela (CIBI-CENABI-01/2022). Furthermore, the information was collected according to the Helsinki Convention and the Venezuelan regulations for this kind of research. Due to the retrospective nature of the study, the CENABI of Venezuela waived informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela. ²Dr. Francisco Battistini Casalta^a Health Sciences School, University of Oriente – Bolívar Nucleus, Ciudad Bolívar, Venezuela. ³Obstetrics and Gynecology Department, San Cristóbal Central Hospital, San Cristóbal, Venezuela. ⁴“José María Vargas” School of Medicine, Central University of Venezuela, Caracas, Venezuela. ⁵“Luis Razetti” School of Medicine, Central University of Venezuela, Caracas, Venezuela. ⁶Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de Las Américas - Institución Universitaria Visión de Las Américas, Pereira, Risaralda, Colombia. ⁷Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon. ⁸Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru. ⁹Infectious Diseases Department, University Hospital of Caracas, Caracas, Venezuela.

Received: 30 September 2022 Accepted: 28 November 2022

Published online: 05 December 2022

References

- Karlinsky A, Kobak D. Tracking excess mortality across countries during the COVID-19 pandemic with the world mortality dataset. *Elife*. 2021;10:e69336.
- The L. COVID-19 in Latin America-emergency and opportunity. *Lancet*. 2021;398(10295):93.
- Litewka SG, Heitman E. Latin American healthcare systems in times of pandemic. *Dev World Bioeth*. 2020;20(2):69–73.
- Lampo M, Hernández-Villena JV, Cascante J, Vincenti-González MF, Forero-Peña DA, Segovia MJ, et al. Signatures of the Venezuelan humanitarian crisis in the first wave of COVID-19: fuel shortages and border migration. *Vaccines*. 2021;9(7):719.
- Tang P, Wang J, Song Y. Characteristics and pregnancy outcomes of patients with severe pneumonia complicating pregnancy: a retrospective study of 12 cases and a literature review. *BMC Pregnancy Childbirth*. 2018;18(1):434.
- Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. *Viruses*. 2020;12(2):194.
- Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol*. 2004;191(1):292–7.
- Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. *Arch Dis Child Fetal Neonatal Ed*. 2005;90(6):F461–5.
- Shek CC, Ng PC, Fung GP, Cheng FW, Chan PK, Peiris MJ, et al. Infants born to mothers with severe acute respiratory syndrome. *Pediatrics*. 2003;112(4):e254.
- Chen L, Li Q, Zheng D, Jiang H, Wei Y, Zou L, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. *N Engl J Med*. 2020;382(25):e100.
- Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of maternal and perinatal mortality and vertical transmission in pregnancies complicated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a systematic review. *Obstet Gynecol*. 2020;136(2):303–12.
- Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ*. 2020;369:m2107.
- Wang X, Chen X, Zhang K. Maternal infection with COVID-19 and increased risk of adverse pregnancy outcomes: a meta-analysis. *J Matern Fetal Neonatal Med*. 2022;35(25):9368–75.
- Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. *CMAJ*. 2021;193(16):E540–e548.
- Martínez-Pérez O, Prats Rodríguez P, Muner Hernández M, Encinas Pardilla MB, Pérez Pérez N, Vila Hernández MR, et al. The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis. *BMC Pregnancy Childbirth*. 2021;21(1):273.
- Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. *JAMA Pediatr*. 2021;175(8):817–26.
- Gajbhiye RK, Sawant MS, Kuppusamy P, Surve S, Pasi A, Prusty RK, et al. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: a systematic review and meta-analysis. *Int J Gynecol Obstet*. 2021;155(1):48–56.
- Chmielewska B, Barratt I, Townsend R, Kalafat E, van der Meulen J, Guroi-Urganci I, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;9(6):e759–72.
- Haye MT, Cartes G, Gutiérrez J, Ahumada P, Krause B, Meriardi M, et al. Maternal and perinatal outcomes in pregnant women with confirmed severe and mild COVID-19 at one large maternity hospital in Chile. *J Matern Fetal Neonatal Med*. 2022;35(25):5917–22.
- Khalil A, Kalafat E, Benlioglu C, O'Brien P, Morris E, Draycott T, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. *Eclinicalmedicine*. 2020;25:100446.
- Maza-Arnedo F, Paternina-Cacedo A, Sosa CG, de Mucio B, Rojas-Suarez J, Say L, et al. Maternal mortality linked to COVID-19 in Latin America: results from a multi-country collaborative database of 447 deaths. *Lancet Reg Health Am*. 2022;12:100269.
- Jering KS, Claggett BL, Cunningham JW, Rosenthal N, Vardeny O, Greene MF, et al. Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19. *JAMA Intern Med*. 2021;181(5):714–7.
- Kasehagen L, Byers P, Taylor K, Kittle T, Roberts C, Collier C, et al. COVID-19-associated deaths after SARS-CoV-2 infection during pregnancy - Mississippi, march 1, 2020–October 6, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(47):1646–8.
- Forero-Peña DA, Carrión-Nessi FS, Omaña-Ávila ÓD, Mendoza-Millán DL, Romero SR, Escalante-Pérez IA, et al. Plasmodium vivax and SARS-CoV-2 co-infection in Venezuela: a case series from the malaria hotspot in Latin America. *Travel Med Infect Dis*. 2022;50:102460.
- Gonçalves BMM, Franco RVP, Rodrigues AS. Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: comparison with non-pregnant women and men. *PLoS One*. 2021;16(12):e0261492.
- Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ*. 2020;370:m3320.
- Rasmussen SA, Jamieson DJ. Pregnancy, postpartum care, and COVID-19 vaccination in 2021. *JAMA*. 2021;325(11):1099–100.
- Abbas-Hanif A, Rezai H, Ahmed SF, Ahmed A. The impact of COVID-19 on pregnancy and therapeutic drug development. *Br J Pharmacol*. 2022;179(10):2108–20.
- Dashraath P, Wong JJJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol*. 2020;222(6):521–31.
- Marcolino MS, Ziegelmann PK, Souza-Silva MVR, Nascimento IJB, Oliveira LM, Monteiro LS, et al. Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: results from the Brazilian COVID-19 registry. *Int J Infect Dis*. 2021;107:300–10.
- Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. *JAMA*. 2020;323(15):1478–87.
- Lucien MAB, Canarie MF, Kilgore PE, Jean-Denis G, Fénélon N, Pierre M, et al. Antibiotics and antimicrobial resistance in the COVID-19 era: perspective from resource-limited settings. *Int J Infect Dis*. 2021;104:250–4.
- Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. *Lancet Glob Health*. 2020;8(12):e1453–4.
- Servante J, Swallow G, Thornton JG, Myers B, Munireddy S, Malinowski AK, et al. Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. *BMC Pregnancy Childbirth*. 2021;21(1):108.

35. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda: National Institutes of Health (US); 2021. Available at: <https://www.covid19treatmentguidelines.nih.gov/>.
36. Gajbhiye RK, Mahajan NN, Waghmare RB, Zala S, Chaaithanya IK, Kuppusamy P, et al. Clinical characteristics, outcomes, & mortality in pregnant women with COVID-19 in Maharashtra, India: results from PregCovid registry. *Indian J Med Res.* 2021;153(5&6):629–36.
37. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–9.
38. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;46(5):846–8.
39. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther.* 2020;5(1):33.
40. Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. *Inflamm Res.* 2020;69(6):599–606.
41. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. *Clin Chim Acta.* 2020;510:475–82.
42. Del Carpio-Orantes L, García-Méndez S, Contreras-Sánchez ER, González-Segovia O, Ahumada-Zamudio A, Velasco-Caicerio AR, et al. Caracterización clínica y del hemograma de pacientes con neumonía por COVID-19 en Veracruz, México. *Revista de Hematol.* 2020;21(4):205–9.
43. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506.
44. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–62.
45. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci.* 2020;63(3):364–74.
46. Para O, Caruso L, Pestelli G, Tangianu F, Carrara D, Maddaluni L, et al. Ferritin as prognostic marker in COVID-19: the FerVid study. *Postgrad Med.* 2022;134(1):58–63.
47. Carubbi F, Salvati L, Alunno A, Maggi F, Borghi E, Mariani R, et al. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. *Sci Rep.* 2021;11(1):4863.
48. Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLoS One.* 2021;16(8):e0256744.
49. Korkusuz R, Karandere F, Senoglu S, Kocoglu H, Yasar KK. The prognostic role of D-dimer in hospitalized COVID-19 patients. *Bratisl Lek Listy.* 2021;122(11):811–5.
50. La Verde M, Riemma G, Torella M, Cianci S, Savoia F, Licciardi F, et al. Maternal death related to COVID-19: a systematic review and meta-analysis focused on maternal co-morbidities and clinical characteristics. *Int J Gynaecol Obstet.* 2021;154(2):212–9.
51. Lokken EM, Taylor GG, Huebner EM, Vanderhoeven J, Hendrickson S, Coler B, et al. Higher severe acute respiratory syndrome coronavirus 2 infection rate in pregnant patients. *Am J Obstet Gynecol.* 2021;225(1):75.e71–16.
52. Forero-Peña DA, Carrión-Nessi FS, Mendoza-Millán DL, Omaña-Ávila OD, Mejía-Bernard MD, Camejo-Ávila NA, et al. First wave of COVID-19 in Venezuela: epidemiological, clinical, and paraclinical characteristics of first cases. *J Med Virol.* 2022;94(3):1175–85.
53. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA.* 2020;324(13):1307–16.
54. McIntosh JJ. Corticosteroid guidance for pregnancy during COVID-19 pandemic. *Am J Perinatol.* 2020;37(8):809–12.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

